Should I refill benzonatate and Bromfed (brompheniramine) for a patient who has not reported a cough in over a year?

Do Not Refill These Medications Without Current Active Symptoms

You are correct to withhold refilling benzonatate and Bromfed for a patient who has not reported cough in over a year and did not complain of cough at the last visit. These are symptomatic treatments for acute conditions, not maintenance medications, and continuing them without active symptoms exposes the patient to unnecessary risks without benefit.

Clinical Reasoning

Benzonatate Should Only Be Used for Active Cough

Benzonatate is FDA-indicated strictly for "symptomatic relief of cough" 1. This means it should only be prescribed when a patient has an active cough requiring treatment. The evidence-based guidelines define acute cough as lasting less than 3 weeks and chronic cough as lasting more than 8 weeks 2. Since your patient:

• Has not refilled in over a year
• Did not report cough at last visit
• Is requesting a refill without documented active symptoms

There is no clinical indication for benzonatate at this time.

Significant Safety Concerns with Benzonatate

The safety profile of benzonatate raises additional concerns about inappropriate prescribing:

• Fatal overdoses have been documented, with 20 deaths out of 31 reported overdose cases, including 5 fatalities in children ≤2 years old 3
• Serious adverse effects can occur within 15 minutes of ingestion, including seizures, cardiac arrest, coma, and respiratory arrest 3
• Recent systematic review found that benzonatate's approval is "founded upon evidence that would not stand up to current regulatory review" with substantial limitations in safety and effectiveness data 4
• Cardiac arrest cases have been reported in both pediatric and adult overdoses 5, 6

Bromfed (Brompheniramine/Pseudoephedrine) Also Requires Active Symptoms

Bromfed is an antihistamine-decongestant combination used for upper respiratory symptoms. Like benzonatate, it is a symptomatic treatment for acute conditions. The FDA labeling emphasizes multiple precautions and contraindications 7, and there is no role for chronic prophylactic use.

What You Should Do

Decline the refill request and instead:

1. Contact the patient to assess current symptoms

   • Ask specifically about presence and duration of cough
   • Inquire about other respiratory symptoms (nasal congestion, post-nasal drip, wheezing)
   • Determine if there's an acute illness prompting the refill request

2. If the patient has active cough, evaluate appropriately:

   • Duration: acute (<3 weeks), subacute (3-8 weeks), or chronic (>8 weeks) 2
   • For chronic cough, identify underlying cause (postnasal drip, asthma, GERD) rather than simply suppressing symptoms 8, 9
   • Consider whether antitussive therapy is truly needed or if treating the underlying cause is more appropriate

3. If no active symptoms exist, explain that:

   • These medications are for symptomatic relief only
   • Keeping unused medications increases risk of accidental ingestion or misuse
   • Patient should contact you when symptoms actually develop

Common Pitfall to Avoid

Do not reflexively refill cough medications as "PRN" maintenance prescriptions. The guideline evidence emphasizes that chronic cough requires diagnostic evaluation to identify and treat the underlying cause 2, 8, not indefinite symptomatic suppression. Antitussive therapy should only be used as adjuvant therapy or when a cause cannot be found 10.

Given the serious safety concerns with benzonatate, particularly the risk of fatal overdose with relatively small amounts 3, 11, and the lack of evidence supporting its effectiveness 4, maintaining an active prescription without documented need represents poor risk-benefit balance.